SPRB - NASDAQ
Spruce Biosciences, Inc.
$49.05
-0.22%Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
At a Glance
Live SnapshotSpruce Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Spruce Biosciences, Inc. Balance Sheet
SPRB • NASDAQ
| Spruce Biosciences, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
48.9M | 38.8M | 96.3M | 24.5M | 42.7M | 157.2M | 3.9M | 4.1M | |
0.0 | 0.0 | 0.0 | 54.6M | 46.2M | 0.0 | 0.0 | 0.0 | |
48.9M | 38.8M | 96.3M | 79.1M | 89M | 157.2M | 3.9M | 4.1M | |
0.0 | 3.2M | 3.9M | 3.3M | 2.5M | 3M | 215K | 411K | |
3.2M | 2.3M | 2M | 1.2M | 396K | 276K | 513K | 250K | |
52.1M | 44.2M | 102.2M | 83.6M | 91.9M | 160.4M | 4.7M | 4.8M | |
NON-CURRENT ASSETS | ||||||||
666K | 934K | 1.2M | 1.4M | 1.5M | 1.9M | 0.0 | 0.0 | |
36K | 0.0 | 0.0 | -54.5M | 32.5M | 0.0 | 0.0 | 0.0 | |
207K | 69K | 582K | 55.2M | 653K | 620K | 40K | 2K | |
909K | 1M | 1.8M | 2M | 34.6M | 2.5M | 40K | 2K | |
53M | 45.2M | 103.9M | 85.6M | 126.5M | 162.9M | 4.7M | 4.8M | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
943K | 1.3M | 3.3M | 1.4M | 2.8M | 3.6M | 1.9M | 2.3M | |
943K | 1.3M | 3.3M | 1.4M | 2.8M | 3.6M | 1.9M | 2.3M | |
0.0 | 11.2M | 3.1M | 9.3M | 5.7M | 3.3M | 1.2M | 405K | |
0.0 | 1.6M | 1.6M | 1.6M | 0.0 | 2.6M | 1.3M | 0.0 | |
317K | 283K | 251K | 139K | 360K | 249K | 0.0 | 0.0 | |
0.0 | 0.0 | 4.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
8.8M | 882K | 11.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
10.1M | 15.2M | 24.5M | 12.4M | 8.9M | 9.8M | 4.3M | 2.7M | |
NON-CURRENT LIABILITIES | ||||||||
419K | 124K | 1.7M | 3.3M | 4.9M | 1.9M | 3.2M | 0.0 | |
0.0 | 282K | 236K | 161K | 73K | 118K | 27.8M | 19.9M | |
419K | 1.1M | 3M | 4.7M | 6.2M | 3.7M | 31M | 19.9M | |
736K | 1M | 1.3M | 1.4M | 1.7M | 1.9M | 0.0 | 0.0 | |
10.5M | 16.4M | 27.4M | 17.2M | 15.1M | 13.5M | 35.3M | 22.6M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 27.1M | -411K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 27.8M | 19.9M | |
0.0 | 4K | 4K | 3K | 3K | 2K | 1K | 1K | |
331.8M | 279.1M | 273.7M | 218.4M | 214.7M | 210.3M | 664K | 411K | |
-289.2M | -250.3M | -197.2M | -149.3M | -103.1M | -60.8M | -31.3M | -18.2M | |
0.0 | 0.0 | 0.0 | -558K | -184K | 0.0 | -27.8M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 27.8M | -19.9M | |
42.5M | 28.8M | 76.5M | 68.5M | 111.4M | 149.4M | -30.6M | -17.8M | |
42.5M | 28.8M | 76.5M | 68.5M | 111.4M | 149.4M | -30.6M | -17.8M | |
SUMMARY | ||||||||
53M | 45.2M | 103.9M | 85.6M | 126.5M | 162.9M | 4.7M | 4.8M | |
36K | 0.0 | 0.0 | 54.6K | 78.7M | 0.0 | 0.0 | 0.0 | |
736K | 2.8M | 4.6M | 6.3M | 6.5M | 6.4M | 4.4M | 0.0 | |
-48.2M | -36M | -91.7M | -18.2M | -36.2M | -150.8M | 521K | -4.1M | |
563,049 | 563,049 | 563,049 | 563,049 | 563,049 | 563,049 | 563,049 | 563,049 |
SEC Filings
SPRB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 20, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 09, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 |
Related Guides
Continue your SPRB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.